PL2274978T3 - Sposoby leczenia niedoboru insulinopodobnego czynnika wzrostu 1 (IGF-1) - Google Patents

Sposoby leczenia niedoboru insulinopodobnego czynnika wzrostu 1 (IGF-1)

Info

Publication number
PL2274978T3
PL2274978T3 PL10009976T PL10009976T PL2274978T3 PL 2274978 T3 PL2274978 T3 PL 2274978T3 PL 10009976 T PL10009976 T PL 10009976T PL 10009976 T PL10009976 T PL 10009976T PL 2274978 T3 PL2274978 T3 PL 2274978T3
Authority
PL
Poland
Prior art keywords
treatment
insulin
growth factor
igf
methods
Prior art date
Application number
PL10009976T
Other languages
English (en)
Inventor
Ross G Clark
Original Assignee
Ipsen Biopharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ipsen Biopharmaceuticals Inc filed Critical Ipsen Biopharmaceuticals Inc
Publication of PL2274978T3 publication Critical patent/PL2274978T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/30—Insulin-like growth factors (Somatomedins), e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575—Hormones
    • G01N2333/65—Insulin-like growth factors (Somatomedins), e.g. IGF-1, IGF-2
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
PL10009976T 2003-09-12 2004-09-09 Sposoby leczenia niedoboru insulinopodobnego czynnika wzrostu 1 (IGF-1) PL2274978T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US50257903P 2003-09-12 2003-09-12
EP10009976.1A EP2274978B1 (en) 2003-09-12 2004-09-09 Methods for treatment of insulin-like growth factor-I(IGF-I) deficiency
EP04817764A EP1667521B1 (en) 2003-09-12 2004-09-09 Methods for treatment of insulin-like growth factor-1 (igf-1) deficiency

Publications (1)

Publication Number Publication Date
PL2274978T3 true PL2274978T3 (pl) 2015-11-30

Family

ID=34619295

Family Applications (1)

Application Number Title Priority Date Filing Date
PL10009976T PL2274978T3 (pl) 2003-09-12 2004-09-09 Sposoby leczenia niedoboru insulinopodobnego czynnika wzrostu 1 (IGF-1)

Country Status (18)

Country Link
US (3) US7258864B2 (pl)
EP (2) EP1667521B1 (pl)
JP (1) JP4738337B2 (pl)
CN (2) CN1870893A (pl)
AT (1) ATE536186T1 (pl)
AU (1) AU2004291833B2 (pl)
CA (1) CA2538342C (pl)
DK (1) DK2274978T3 (pl)
ES (2) ES2541673T3 (pl)
HU (1) HUE027218T2 (pl)
IL (1) IL174209A (pl)
MA (1) MA28091A1 (pl)
NZ (1) NZ545940A (pl)
PL (1) PL2274978T3 (pl)
PT (1) PT2274978E (pl)
TN (1) TNSN06082A1 (pl)
WO (1) WO2005049792A2 (pl)
ZA (1) ZA200602183B (pl)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2274978T3 (en) * 2003-09-12 2015-06-15 Ipsen Biopharmaceuticals Inc Methods of treating an insulin-like growth factor-I (IGF-I) deficiency
EP1901770B1 (en) * 2005-06-02 2014-12-24 Ipsen Biopharmaceuticals, Inc. Gh and igf-1 for treatment of growth disorders
BRPI0812768A2 (pt) * 2007-06-08 2014-12-02 Massachusetts Inst Technology Igf para o tratamento de síndrome de rett e transtornos sinápticos.
US20090177142A1 (en) 2008-01-09 2009-07-09 Smiths Medical Md, Inc Insulin pump with add-on modules
US8986253B2 (en) 2008-01-25 2015-03-24 Tandem Diabetes Care, Inc. Two chamber pumps and related methods
US8408421B2 (en) 2008-09-16 2013-04-02 Tandem Diabetes Care, Inc. Flow regulating stopcocks and related methods
EP2334234A4 (en) 2008-09-19 2013-03-20 Tandem Diabetes Care Inc DEVICE FOR MEASURING THE CONCENTRATION OF A SOLVED SUBSTANCE AND CORRESPONDING METHOD
CA2643529C (en) * 2008-11-06 2019-05-21 Kenneth W. Adams Method and composition for enhancement of male erectile function
US9250106B2 (en) 2009-02-27 2016-02-02 Tandem Diabetes Care, Inc. Methods and devices for determination of flow reservoir volume
US8573027B2 (en) 2009-02-27 2013-11-05 Tandem Diabetes Care, Inc. Methods and devices for determination of flow reservoir volume
US8759299B2 (en) 2009-07-22 2014-06-24 Ipsen Pharma S.A.S. Analogues of insulin-like growth factor-1 (IGF-1) having amino acid substitution at position 59
WO2011011071A2 (en) * 2009-07-22 2011-01-27 Ipsen Pharma S.A.S. Analogues of insulin-like growth factor-1 (igf-1)
CA2921304C (en) 2009-07-30 2018-06-05 Tandem Diabetes Care, Inc. Infusion pump system with disposable cartridge having pressure venting and pressure feedback
US20130261059A1 (en) * 2010-05-26 2013-10-03 The Children's Hospital Of Philadelphia Compositions and Methods for the Diagnosis and Treatment of Primary Insulin-Like Growth Factor Deficiency (PIGFD) and Idiopathic Short Stature (ISS)
WO2012094755A1 (en) * 2011-01-14 2012-07-19 Theratechnologies Inc. Assessment of igf-1 levels in hiv-infected subjects and uses thereof
US9180242B2 (en) 2012-05-17 2015-11-10 Tandem Diabetes Care, Inc. Methods and devices for multiple fluid transfer
US9555186B2 (en) 2012-06-05 2017-01-31 Tandem Diabetes Care, Inc. Infusion pump system with disposable cartridge having pressure venting and pressure feedback
US10201656B2 (en) 2013-03-13 2019-02-12 Tandem Diabetes Care, Inc. Simplified insulin pump for type II diabetics
US9173998B2 (en) 2013-03-14 2015-11-03 Tandem Diabetes Care, Inc. System and method for detecting occlusions in an infusion pump
US9492608B2 (en) 2013-03-15 2016-11-15 Tandem Diabetes Care, Inc. Method and device utilizing insulin delivery protocols
EP3233109A4 (en) * 2014-12-16 2018-07-18 Puretein Bioscience, LLC Methods for increasing serum igf-1 in an animal
WO2019075404A2 (en) * 2017-10-13 2019-04-18 The Metrohealth System IGF-1 (INSULIN GROWTH FACTOR) AS A THERAPY FOR CARDIAC ARRHYTHMIAS
US10288629B1 (en) * 2017-12-19 2019-05-14 Aeterna Zentaris, Inc. Method of assessing growth hormone deficiency in humans by a macimorelin containing composition
KR102245539B1 (ko) * 2018-02-12 2021-04-29 주식회사 지앤피바이오사이언스 코어-쉘 구조의 마이크로 입자를 유효성분으로 포함하는 성장인자 유전자 발현 증가용 조성물
EP3776801A4 (en) 2018-04-10 2021-12-22 Tandem Diabetes Care, Inc. SYSTEM AND METHOD FOR CHARGING BY INDUCTION A MEDICAL DEVICE

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4411890A (en) 1981-04-14 1983-10-25 Beckman Instruments, Inc. Synthetic peptides having pituitary growth hormone releasing activity
US4263428A (en) 1978-03-24 1981-04-21 The Regents Of The University Of California Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
ATE12348T1 (de) 1980-11-10 1985-04-15 Gersonde Klaus Prof Dr Verfahren zur herstellung von lipid-vesikeln durch ultraschallbehandlung, anwendung des verfahrens und vorrichtung zur durchfuehrung des verfahrens.
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
JPS58118008A (ja) 1982-01-06 1983-07-13 Nec Corp デ−タ処理装置
DE3374837D1 (en) 1982-02-17 1988-01-21 Ciba Geigy Ag Lipids in the aqueous phase
DE3218121A1 (de) 1982-05-14 1983-11-17 Leskovar, Peter, Dr.-Ing., 8000 München Arzneimittel zur tumorbehandlung
EP0102324A3 (de) 1982-07-29 1984-11-07 Ciba-Geigy Ag Lipide und Tenside in wässriger Phase
ATE95236T1 (de) 1983-04-25 1993-10-15 Chiron Corp Hybrid-dns-synthesis von reifen insulinaehnlichen wachstumsfaktoren.
IL71991A (en) 1983-06-06 1994-05-30 Genentech Inc Preparation of human FGI and FGE in their processed form through recombinant AND tranology in prokaryotes
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
EP0350973B1 (de) 1983-09-26 1997-11-05 Udo Dr. Ehrenfeld Mittel und Erzeugnis für die Diagnose und Therapie von Tumoren sowie zur Behandlung von Schwächen der zelligen und humoralen Immunabwehr
US4615885A (en) 1983-11-01 1986-10-07 Terumo Kabushiki Kaisha Pharmaceutical composition containing urokinase
US4704355A (en) 1985-03-27 1987-11-03 New Horizons Diagnostics Corporation Assay utilizing ATP encapsulated within liposome particles
EP0235205B1 (en) 1985-08-22 1992-10-28 Gropep Pty. Ltd. Peptide analogues of mammalian insulin-like growth factor-1
SE8505922D0 (sv) 1985-12-13 1985-12-13 Kabigen Ab Construction of an igg binding protein to facilitate downstream processing using protein engineering
EP0308500B1 (en) 1987-04-06 1993-06-16 Celtrix Pharmaceuticals, Inc. Human somatomedin carrier protein subunits and process for producing them
EP0288451B1 (en) 1987-04-23 1994-08-10 Monsanto Company Secretion of insulin-like growth factor 1 in E. coli
US5057417A (en) 1987-06-12 1991-10-15 Genentech, Inc. Compositions and methods for the synthesis of growth hormone receptor and growth hormone binding protein
US4876242A (en) 1987-09-21 1989-10-24 Merck & Co., Inc. Human insulin-like growth factor analoges with reduced binding to serum carrier proteins and their production in yeast
US4892538A (en) 1987-11-17 1990-01-09 Brown University Research Foundation In vivo delivery of neurotransmitters by implanted, encapsulated cells
US5283187A (en) 1987-11-17 1994-02-01 Brown University Research Foundation Cell culture-containing tubular capsule produced by co-extrusion
ATE116335T1 (de) 1987-12-24 1995-01-15 Gropep Pty Ltd Peptid-analoge vom insulinähnlichen wachstums- faktor 1 (igf-1) oder faktor 2 (igf-2).
US5470828A (en) 1987-12-24 1995-11-28 Gropep Pty. Ltd. Peptide analogs of insulin-like growth factor II
DK131988A (da) 1988-03-11 1989-09-12 Erasmus University Igf-bindingsprotein, dna-struktur, der koder for igf-bindingsproteinet og vektor indeholdende denne dna-struktur
US5258287A (en) 1988-03-22 1993-11-02 Genentech, Inc. DNA encoding and methods of production of insulin-like growth factor binding protein BP53
EP0418230B1 (en) 1988-04-12 1995-12-27 Amgen Boulder Inc. Method for potentiating and inhibiting insulin-like growth factor activity
GB8826451D0 (en) 1988-11-11 1988-12-14 Sandoz Ltd Improvements in/relating to organic compounds
IL92816A0 (en) 1988-12-22 1990-09-17 Biogrowth Inc Recombinant dna molecules,hosts,processes and human somatomedin carrier protein-like polypeptides
CA2025907A1 (en) 1989-09-21 1991-03-22 Franklin D. Collins Method of transporting compositions across the blood brain barrier
US5681814A (en) 1990-06-07 1997-10-28 Genentech, Inc. Formulated IGF-I Composition
US5126324A (en) 1990-06-07 1992-06-30 Genentech, Inc. Method of enhancing growth in patients using combination therapy
US5210017A (en) 1990-11-19 1993-05-11 Genentech, Inc. Ligand-mediated immunofunctional hormone binding protein assay method
US5593844A (en) 1990-11-19 1997-01-14 Genentech, Inc. Ligand-mediated immunofunctional hormone binding protein assay method
US5198340A (en) 1991-01-17 1993-03-30 Genentech, Inc. Assay for free igf-i, igf-ii, and gh levels in body fluids
US5187151A (en) 1991-02-12 1993-02-16 Genentech, Inc. Use of binding protein with igf-i as an anabolic growth promoting agent
US5206235A (en) 1991-03-20 1993-04-27 Merck & Co., Inc. Benzo-fused lactams that promote the release of growth hormone
ES2101865T3 (es) 1991-08-01 1997-07-16 Genentech Inc Igf-1 para mejorar el estado neural.
EP0646178A1 (en) 1992-06-04 1995-04-05 The Regents Of The University Of California expression cassette with regularoty regions functional in the mammmlian host
NZ255461A (en) 1992-08-20 1996-12-20 Biotechnology & Biolog Science Specific binding molecules for insulin-like-growth-factor-1 (igf-1), antigens capable of generating them and their use in enhancing igf-1 activity
WO1995017423A1 (en) 1993-12-23 1995-06-29 Novo Nordisk A/S Compounds with growth hormone releasing properties
CA2179598A1 (en) 1993-12-23 1995-06-29 Nils Langeland Johansen Compounds with growth hormone releasing properties
US6207640B1 (en) * 1994-04-07 2001-03-27 Genentech, Inc. Treatment of partial growth hormone insensitivity syndrome
US5824642A (en) 1994-04-07 1998-10-20 Genentech, Inc. Treatment of partial growth hormone insensitivity syndrome
US5646113A (en) * 1994-04-07 1997-07-08 Genentech, Inc. Treatment of partial growth hormone insensitivity syndrome
US5798337A (en) 1994-11-16 1998-08-25 Genentech, Inc. Low molecular weight peptidomimetic growth hormone secretagogues
SE9501472D0 (sv) 1995-04-21 1995-04-21 Pharmacia Ab Truncated IGF-I
US5622932A (en) 1995-05-05 1997-04-22 Eli Lilly And Company IGF-1 superagonists
US5741776A (en) * 1995-05-22 1998-04-21 Genentech, Inc. Method of administration of IGF-I
US5565428A (en) 1995-05-22 1996-10-15 Genentech, Inc. Method of administration of IGF-I
JP3576170B2 (ja) 1995-05-26 2004-10-13 セラテクノロジーズ・インコーポレーテッド 生物学的活性が増加したキメラ脂肪体プロｇｒｆ類似体
WO1997039032A1 (en) 1996-04-17 1997-10-23 Neurocrine Biosciences, Inc. Ligand inhibitors of insulin-like growth factor binding proteins and methods of use therefor
US6121416A (en) 1997-04-04 2000-09-19 Genentech, Inc. Insulin-like growth factor agonist molecules
US6420518B1 (en) 1997-04-04 2002-07-16 Genetech, Inc. Insulin-like growth factor agonist molecules
IL143834A0 (en) 1999-01-06 2002-04-21 Genentech Inc Insulin-like growth factor (igf) i mutant variants
DK2274978T3 (en) 2003-09-12 2015-06-15 Ipsen Biopharmaceuticals Inc Methods of treating an insulin-like growth factor-I (IGF-I) deficiency

Also Published As

Publication number Publication date
TNSN06082A1 (en) 2007-10-03
HUE027218T2 (en) 2016-10-28
JP2007505140A (ja) 2007-03-08
PT2274978E (pt) 2015-07-09
ES2541673T3 (es) 2015-07-23
EP2274978A1 (en) 2011-01-19
AU2004291833A1 (en) 2005-06-02
AU2004291833B2 (en) 2010-08-26
IL174209A (en) 2012-12-31
MA28091A1 (fr) 2006-08-01
US20080058259A1 (en) 2008-03-06
EP2274978B1 (en) 2015-05-20
US8133862B2 (en) 2012-03-13
CN102861321A (zh) 2013-01-09
CA2538342A1 (en) 2005-06-02
WO2005049792A2 (en) 2005-06-02
US20050059598A1 (en) 2005-03-17
IL174209A0 (en) 2006-08-01
CN1870893A (zh) 2006-11-29
EP1667521B1 (en) 2011-12-07
EP1667521A2 (en) 2006-06-14
NZ545940A (en) 2009-12-24
US7517530B2 (en) 2009-04-14
DK2274978T3 (en) 2015-06-15
ES2373783T3 (es) 2012-02-08
JP4738337B2 (ja) 2011-08-03
ATE536186T1 (de) 2011-12-15
US7258864B2 (en) 2007-08-21
CA2538342C (en) 2013-01-08
EP1667521A4 (en) 2008-07-02
US20090270323A1 (en) 2009-10-29
ZA200602183B (en) 2007-07-25
WO2005049792A3 (en) 2006-02-23

Similar Documents

Publication Publication Date Title
IL174209A0 (en) Methods for treatment of insulin like growth factor-1 (igf-1) deficiency
Busenlechner et al. Long-term implant success at the Academy for Oral Implantology: 8-year follow-up and risk factor analysis
Khandelwal et al. Conventional SLA and chemically modified SLA implants in patients with poorly controlled type 2 diabetes mellitus–a randomized controlled trial
Corbella et al. Long‐term outcomes for the treatment of atrophic posterior maxilla: a systematic review of literature
Mourya et al. Socket‐shield technique for implant placement to stabilize the facial gingival and osseous architecture: A systematic review
Grossmann et al. Success and survival of single dental implants placed in sites of previously failed implants
GR3036901T3 (en) Treatment of partial growth hormone insensitivity syndrome
Yang et al. Sihler-stain study of buccal nerve distribution and its clinical implications
Litsas Growth hormone therapy and craniofacial bones: a comprehensive review
NO940180D0 (no) Anvendelse av IGF-I
Stefansson et al. Hemodynamic and metabolic effects of ketamine anesthesia in the geriatric patient
US6818665B2 (en) Treatment of obstructive sleep apnea
Wang et al. Sinus elevation through transcrestal window approach and delayed implant placement in 1-to 2-mm residual alveolar bone: a case report
Constans Plasma glucose goals and therapeutic management in elderly diabetic patients
Kwon et al. Pathologic mandibular fracture after biting crab shells following ramal bone graft
WO2005020898A3 (en) Methods of reducing visceral fat by increasing levels of insulin-like growth factor-i (igf-i)
Herold et al. Sub total unilateral oculomotor nerve palsy in a Le Fort I osteotomy
Ahn et al. A survey of dental treatment under outpatient general anesthesia at Chonbuk National University Dental Hospital between 2014~ 2017
Kim et al. Does desflurane need more irrigating-pump pressure for the visibility in arthroscopic shoulder surgery than sevoflurane?
Billington The challenge of obesity management in primary care
Bock et al. Complications of orthodontic–orthognathic surgery treatment in mentally handicapped patients
Casanveva Consensus on the diagnosis and treatment of acromegaly
EP0916345B1 (en) Human growth hormone for treating anorexia nervosa
Salles et al. Oriental Medicine Technique in the Treatment of Stress and Quality of Life in Patients with Chronic Problems
Peters et al. PITFALLS AND PREJUDICES-THE IMPACT OF ALCOHOL ON MEDICAL CARE: Alcoholism and its treatment